Development of an innovative immunotherapy against melanoma
We aim to generate a vaccine for malignant melanoma based on melanoma-associated endogenous retrovirus (MERV) antigens. Predicted and validated antigens are inserted into an influenza virus vector and the resulting vaccine (MelFlu) is tested in preclinical assays.
1 043 000.00€
BIOLOGICAL SCIENCES / TECHNOLOGIES